Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb
Weigelin B., Bolaños E., Teijeira A., Martinez-Forero I., Labiano S., Azpilikueta A., Morales-Kastresana A., Quetglas JI., Wagena E., Sánchez-Paulete AR., Chen L., Friedl P., Melero I.
SignificanceImmunotherapy of cancer with immunomodulatory agents is achieving significant efficacy in an important fraction of patients. The stimulatory inducible receptor of T and NK lymphocytes known as CD137 or 4-1BB is being stimulated with agonist antibodies to enhance antitumor immunity in clinical trials. In addition, the intracellular signaling domain of CD137 is crucial as a component of successful anti-leukemia therapies with chimeric antigen receptors transduced into adoptively transferred T lymphocytes. In this study the marked synergistic effects of adoptive T cell and agonist anti-CD137 mAb therapies are studied, providing in vivo evidence for improved, more sustained and focused tumoricidal functions of antitumor cytotoxic T lymphocytes when under the influence of CD137-targeted pharmacological stimulation with immunostimulatory monoclonal antibodies.